Managing Transfer to Women and Children on AndroGel (testosterone topical): The HealthRX Step-by-Step Protocol

At a glance

• Incidence in post-marketing data: The FDA identified multiple pediatric virilization cases after 2009 review, prompting the Black Box Warning update; exact transfer incidence in clinical use is not captured in a single trial denominator
• Androgel Phase III trial reference: The key AndroGel registration trials (Swerdloff et al., 2000) focused on hypogonadal males; transfer risk was characterized separately through post-marketing surveillance
• Typical timeline for virilization signs: Clitoral or penile enlargement, pubic hair growth, and advanced bone age in children can appear within weeks to months of repeated exposure
• First-line management: Immediate barrier precautions, confirmed site coverage with clothing, rigorous handwashing after every application
• Escalation threshold: Any exposed child with a clinical sign of virilization, or any exposed woman with androgenic symptoms (acne, clitoral enlargement, deepened voice), requires serum testosterone measurement and specialist referral
• Discontinuation criteria: Continued transfer despite full protocol adherence, confirmed virilization in an exposed child, or patient inability to reliably follow prevention steps

Why Transfer Happens: The Pharmacokinetic Reality

AndroGel delivers testosterone through a hydroalcoholic gel applied daily to the shoulders, upper arms, or abdomen. After application, a significant fraction of the dose remains on the skin surface before full percutaneous absorption occurs. FDA pharmacokinetic labeling for testosterone topical products confirms that absorption into the systemic circulation continues for several hours, meaning residue capable of transferring remains on skin well past application.

A 2010 study by Stahlman et al., published in the Journal of the American Academy of Dermatology, demonstrated that uncovered application sites transferred measurable testosterone to female partners through a single 15-minute skin contact session. Serum testosterone in female subjects rose significantly above baseline. Covering the application site with a cotton T-shirt reduced transfer by approximately 95% compared with uncovered skin contact. This is the single most clinically important prevention data point in the literature.

Children are at disproportionately higher risk than adults for two reasons. First, their endogenous testosterone baseline is near zero, so even a small transferred dose produces a large relative increase. Second, they are more likely to have prolonged or repeated skin-to-skin contact with a caregiver, such as being held, carried, or bathed by the patient.

Step 1. Baseline Risk Assessment Before Starting AndroGel

Before the first tube is dispensed, the prescriber should document answers to these questions in the chart:

1. Does anyone under 18 live in or regularly visit the patient's home?
2. Does the patient have a female sexual partner?
3. Who provides hands-on physical care (bathing, feeding, holding) for children in the household?
4. Does the patient have a job or caregiving role involving sustained skin contact with others?

Patients who answer yes to any of the first two questions should receive written and verbal counseling before the prescription is filled, not at a later follow-up. The Endocrine Society Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism (Bhasin et al., 2018) explicitly states that household contacts must be considered when selecting a testosterone delivery route.

If a patient cannot reliably follow prevention steps due to living situation, cognitive barriers, or physical limitations, an alternative delivery route (intramuscular testosterone, subcutaneous pellets, or nasal testosterone gel) should be discussed before initiating topical therapy. The Endocrine Society guideline supports this individualized route selection.

Step 2. The Application Protocol Every Patient Must Follow

Give this as a numbered checklist, not a paragraph of instructions. Patients under time pressure remember lists.

1. Apply gel at the same time each day, ideally in the morning, when physical contact with household members is easier to control for several hours.
2. Apply only to the shoulders, upper arms, or abdomen as directed on the current FDA-approved labeling. Never apply to the genitals, face, or chest if a nursing infant could contact those areas.
3. Wash hands thoroughly with soap and water immediately after application. This step is not optional. Residue on palms can transfer to any surface or person touched afterward.
4. Wait for the gel to dry completely (typically 5 minutes) before dressing.
5. Cover the application site with a shirt or clothing before any skin-to-skin contact with a woman or child. The Stahlman et al. 2010 data confirm clothing coverage is the highest-impact single barrier intervention.
6. If physical contact with a child or partner occurs before washing and covering, the contact person should wash the exposed skin area with soap and water as soon as possible.
7. Wash the application site before sexual contact or before holding a child, particularly if more than 2 hours have not passed since application.

Post bathing or showering resets the skin surface and eliminates residue. Patients who shower after applying gel lose dose effectiveness. The most practical schedule for households with young children is: apply gel, wait for drying, dress, complete the morning routine, and schedule direct child contact for times when a shirt has been worn for at least 2 hours.

Step 3. Recognizing Exposure in a Woman

Female partners of AndroGel patients can develop androgen excess from repeated low-level transfer. The signs are often subtle at first and can be mistaken for hormonal fluctuation or polycystic ovary syndrome.

Symptoms to assess at each patient visit include:

• New or worsening acne on the face, chest, or back in the partner
• Increased facial or body hair growth (hirsutism)
• Scalp hair thinning or loss in a male pattern
• Irregular menstrual cycles or amenorrhea
• Clitoral enlargement (requires direct patient report or clinical exam)
• Changes in libido disproportionate to other factors
• Deepening of the voice (a later and often irreversible sign)

Any woman with two or more of these symptoms who has regular skin contact with an AndroGel patient should have a serum total testosterone drawn. The American Urological Association and the Endocrine Society both recognize serum testosterone measurement as the appropriate confirmatory step for suspected secondary androgen exposure.

Normal total testosterone in adult women is generally 15 to 70 ng/dL. Values above this range in the context of AndroGel household exposure are consistent with secondary transfer until proven otherwise. If the value is elevated, the AndroGel patient's application technique must be reassessed immediately, and if signs persist after technique correction, a route change is indicated.

Step 4. Recognizing Exposure in a Child

Pediatric virilization from secondary testosterone exposure can progress rapidly. The FDA's 2009 safety alert described cases of children as young as 9 months who developed pubic hair, clitoral or penile enlargement, and advanced bone age after regular contact with a caregiver applying testosterone gel.

Clinical signs to screen for at each well-child or pediatric visit in known exposure households:

• Pubic, axillary, or facial hair growth inappropriate for age
• Acne in a child under typical acne onset age (pre-adolescent)
• Accelerated linear growth velocity
• Genital enlargement (penis, clitoris, or labial changes)
• Behavioral changes including aggression or mood liability (less specific, but reported)
• Body odor onset before expected puberty

If any of these signs are present, the child requires serum testosterone measurement and referral to a pediatric endocrinologist. Bone age X-ray (left wrist and hand) should be obtained to assess for advanced skeletal maturation, which can compromise final adult height if prolonged. The American Academy of Pediatrics guidance on precocious puberty (Fuqua, 2017) outlines the diagnostic workup and confirms that exogenous androgen exposure must be excluded before a diagnosis of idiopathic precocious puberty is made.

Do not delay referral waiting for a follow-up testosterone value. Bone age advancement is irreversible.

Step 5. Escalation Criteria

Move immediately to the next level of intervention when any of the following apply:

• A child has any clinical sign of virilization, regardless of serum testosterone level
• A female partner has serum testosterone above 70 ng/dL on a confirmed repeat measurement
• Signs of virilization in a woman include voice deepening or irreversible clitoral enlargement
• The patient cannot consistently follow the application protocol despite documented counseling
• A second exposure event occurs after the protocol was believed to be in place

At this escalation point, the prescriber should switch AndroGel to an alternative testosterone delivery route. Injectable testosterone cypionate or enanthate, subcutaneous testosterone pellets, and intranasal testosterone (Natesto) carry no documented secondary transfer risk. The Endocrine Society guideline confirms that patients with household exposure concerns are appropriate candidates for non-topical routes.

Referral to an endocrinologist for the patient and to a pediatric endocrinologist or gynecologist for the exposed individual should occur at the same visit as the route change discussion. Do not treat these as sequential steps.

What Success and Failure Look Like

Success at 4 weeks: No new androgenic symptoms reported by the partner or observed in the child. Application technique re-audit confirms consistent handwashing, site coverage, and timing. Serum testosterone in any previously exposed individual is trending toward or within normal range.

Failure at 4 weeks: Any persistent or new androgenic sign in an exposed individual, patient reporting difficulty maintaining the protocol, or serum testosterone in an exposed person remaining elevated. At this threshold, route change is no longer optional.

Failure immediately: A child with bone age advancement confirmed on X-ray, a child with genital enlargement, or a woman with voice change. These outcomes require specialist management and AndroGel discontinuation without further protocol attempts.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://pubmed.ncbi.nlm.nih.gov/11134099/
• Stahlman J, Britto M, Fitzpatrick S, et al. Serum testosterone levels in non-treated females after contact with male patients treated with 1% testosterone gel. J Am Acad Dermatol. 2010;63(1):91-100. https://pubmed.ncbi.nlm.nih.gov/20541277/
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
• FDA Drug Safety Communication: FDA Warns About Serious Safety Concerns with Testosterone Gels. U.S. Food and Drug Administration, 2009. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-safety-consequences-testosterone-gel
• AndroGel (testosterone) 1% Prescribing Information. AbbVie Inc. Current labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021015s041lbl.pdf
• Fuqua JS. Treatment and Outcomes of Precocious Puberty: An Update. J Clin Endocrinol Metab. 2013;98(6):2198-2207. https://pubmed.ncbi.nlm.nih.gov/27940735/
• American Urological Association. Testosterone Deficiency Guideline. 2022. https://www.auanet.org/guidelines-and-resources/guidelines/testosterone-deficiency-guideline
• Rogol AD, Tkachenko N, Bryson N. Natesto, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016;4(1):46-54. https://pubmed.ncbi.nlm.nih.gov/26634922/
• Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250-1263. https://pubmed.ncbi.nlm.nih.gov/24119423/